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OBJECTIVES We sought to determine whether angiotensin-converting enzyme inhibition (ACE-I) (i.e.,
quinapril) prevents transient ischemia (exertional and spontaneous) in patients with coronary
artery disease (CAD).
BACKGROUND It is known that ACE-I reduces the risk of death, myocardial infarction (MI), and other
CAD-related outcomes in high-risk patients. Numerous studies have confirmed that ACE-I
improves coronary flow and endothelial function. Whether ACE-I also decreases transient
ischemia is unclear, because no studies have been adequately designed or sufficiently powered
to evaluate this issue.
METHODS Using a randomized, double-blinded, placebo-controlled, multicenter design, we enrolled 336
CAD patients with stable angina. None had uncontrolled hypertension, left ventricular (LV)
dysfunction, or recent MI, and all developed electrocardiographic (ECG) evidence of
ischemia during exercise. They were randomly assigned to one of two groups: 40 mg/day
quinapril (n  177) or placebo (n  159) for 8 weeks. Patients then entered an additional
eight-week treatment phase to examine the full dose range. Those assigned to 40 mg
quinapril continued that dose and those assigned to placebo were titrated to 80 mg/day.
Treadmill testing, the Seattle Angina Questionnaire, and ambulatory ECG monitoring were
used to assess responses at baseline and at 8 and 16 weeks.
RESULTS The groups did not differ significantly at entry or in terms of indexes assessing myocardial
ischemia at 8 or 16 weeks of treatment. In this low-risk population, ACE-I was not associated
with serious adverse events.
CONCLUSIONS Our findings suggest short-term ACE-I in CAD patients without hypertension, LV dysfunction,
or acute MI is not associated with significant effects on transient ischemia. (J Am Coll Cardiol
2003;42:2049–59) © 2003 by the American College of Cardiology Foundation
Numerous trials have documented that angiotensin-
converting enzyme inhibition (ACE-I) reduces the risk of
death, myocardial infarction (MI), and other adverse out-
comes in patients with or at high risk of coronary artery
disease (CAD), acute MI, or left ventricular (LV) dysfunc-
tion (1–8). Recent evidence also indicates ACE-I improves
coronary flow and endothelial functional abnormalities that
may limit blood flow in patients with ischemic heart disease
(9–12). Other reports, when considered in aggregate, have
suggested variability in the effects ACE-I in patients with
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signs or symptoms of myocardial ischemia (13–35). How-
ever, methodologic limitations related to a small sample
size, confounding conditions, and other factors prevent
definitive conclusions from these reports. Clearly, appropri-
ately powered, randomized, placebo-controlled trials in
lower risk chronic ischemic heart disease patients are nec-
essary to better address whether ACE-I reduces the risk of
adverse outcomes by preventing transient ischemia. Accord-
ingly, we conducted a controlled trial in low-risk patients
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with chronic, stable ischemia to assess the effects of ACE-I
(quinapril) on transient myocardial ischemia.
METHODS
The Quinapril Anti-ischemia and Symptoms of Angina
Reduction (QUASAR) trial, a double-blinded, randomized,
placebo-controlled, parallel-group trial involving 47 sites
(Appendix), was designed to investigate whether ACE-I
with quinapril lessens the frequency and severity of transient
ischemia in low-risk patients with CAD. Transient isch-
emia was defined as ischemia occurring during exercise and
ischemia occurring spontaneously. Quinapril was chosen
because it has a high affinity for ACE in the vascular wall,
slowly dissociates once bound (36), and improves coronary
flow (11) and coronary endothelial function (9) in the
patient population of interest.
The study was investigator-initiated and industry-
sponsored. A steering committee was responsible for pro-
tocol development and direction of study conduct. The
protocol was approved by local ethics committees, and all
patients provided written, informed consent.
Patients. Men or women (postmenopausal or nonpregnant
using adequate contraception) were eligible if they had
CAD documented by any of the following: 60% diameter
stenosis of one or more major coronary artery, Q-wave MI,
or an abnormal stress test by echocardiography or radionu-
clide imaging. Patients meeting these criteria were also
required to have had an abnormal exercise treadmill test
(ETT), using the Asymptomatic Cardiac Ischemia Pilot
(ACIP) protocol (37), limited by angina pectoris occurring
within 8 min and accompanied by an ischemic-type ST-
segment response. This was defined as 1.0-mm ST-
segment depression in two or more contiguous electrocar-
diographic (ECG) leads over at least three beats that was
reversible. Medications included 80 mg/day aspirin or an-
other antiplatelet agent and those required for angina
pectoris (e.g., sublingual nitroglycerin, long-acting nitrates,
calcium antagonists, beta-blockers), provided the drug and
dose had been stable for at least two weeks before entering
the baseline period.
Exclusions included conditions: 1) likely to confound the
interpretation of response measures (e.g., severe broncho-
spastic lung disease, cor pulmonale, recent unstable angina,
angina precipitated by correctable anemia or metabolic
factors, significant uncorrected valvular or congenital heart
disease, recent [6 months] revascularization, LV hypertro-
phy with ST-T-segment abnormalities, paced rhythm, un-
controlled ventricular or supraventricular arrhythmias, left
or right bundle branch block, atrioventricular conduction
defects and/or resting ST-segment depression [0.9 mm],
insulin-dependent or uncontrolled type 2 diabetes [HbA1C
9], and/or initiation or termination of hormone replace-
ment therapy or lipid-lowering drugs within two months);
2) in which ACE-I might pose an increased risk of severe
hypotension (e.g., renal artery stenosis, hypotension); and 3)
where ACE-I was definitely indicated (e.g., recent MI,
uncontrolled hypertension, heart failure). Patients with any
exposure to ACE-I within two weeks of entering the
baseline period also were excluded.
Study design. The QUASAR design had three study
periods (Fig. 1). After a two- to four-week, single-blinded,
placebo-baseline period, patients were randomly assigned to
a double-blinded treatment period with placebo (group 1) or
40 mg/day quinapril (group 2) for eight weeks. They then
entered an extended double-blinded treatment period (ad-
ditional eight weeks) during which group 1 was given 80
mg/day quinapril and group 2 continued 40 mg/day
quinapril. Randomization was stratified by center and beta-
blocker use within the previous 30 days (absent or present)
to ensure a 1:1 distribution in each group. Patients per-
formed an ETT at the end of the baseline period (single-
blinded placebo, period 1) and at 8 weeks (double-blinded
treatment, period 2) and 16 weeks (end of extended double-
blinded treatment, period 3). A 48-h ambulatory ECG and
responses to the Seattle Angina Questionnaire (38) were
recorded at baseline and at 4, 8, and 16 weeks. Assessments
included a monthly clinical evaluation, adverse event mon-
itoring, and serum electrolyte and renal function tests at 4
and 12 weeks.
Abbreviations and Acronyms
ACE-I  angiotensin-converting enzyme
inhibition/inhibitor
CAD  coronary artery disease
ECG  electrocardiogram/electrocardiographic
ETT  exercise treadmill test/testing
LV  left ventricular
MI  myocardial infarction
QUASAR  Quinapril Anti-ischemia and Symptoms
of Angina Reduction trial
Figure 1. Schematic of the QUASAR study design. Q  quinapril; R 
randomize. After a 2- to 4-week single-blind placebo period (Period 1)
patients were randomly assigned to two groups. Group 1 received double-
blind placebo for 8 weeks (Period 2) and then double-blind Q 80 mg/day
for 8 weeks (Period 3). In the latter, there was a 1 week dose titration from
40 to 80 mg/day. Group 2 received double-blind Q 40 mg/day for 8 weeks
(Period 2) followed by double-blind Q 40 mg/day for an additional 8 weeks
(Period 3).
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The primary efficacy parameter was time to onset 1-mm
ST-segment depression during ETT, comparing the treat-
ment groups at eight weeks (end of period 2). Secondary
efficacy parameters included time to onset of angina during
exercise, exercise duration, number and duration of ischemic
episodes during ambulatory ECG monitoring, ischemic
burden (product of ischemic episode number, duration, and
magnitude of ischemic ST-segment depression during am-
bulatory ECG monitoring), and severity of angina by the
Seattle Angina Questionnaire (38). Other efficacy parameters
included all these measures at 16 weeks (end of period 3).
Assessment of transient ischemia. Ischemia during exer-
cise stress was evaluated with treadmill testing using the
ACIP protocol (37) for a ramp-like increase in work,
avoiding the large step increases of the Bruce protocol (39).
Treadmill tests were done in the morning, in the same
laboratories at each site, and at trough plasma levels for back-
ground anti-anginal medications. Before and during ETT,
12-lead ECGs, blood pressure, and pertinent exercise-related
symptom data were recorded on standardized forms for inter-
pretation by the Core Exercise Laboratory (St. Louis Univer-
sity, St. Louis, Missouri), which was masked as to the clinical
data and group assignment. Exercise-induced ECG ischemia
was defined as the new development of ST-segment depres-
sion1 mm over baseline. When baseline resting ST-segment
depression (0.9 mm) was present, an additional 1-mm
ST-segment depression was required. Exercise ECGs were
analyzed using customized software, as previously described
(40).
Ischemia occurring spontaneously during daily life was
assessed by ambulatory ECG recordings for 48 h by a Rozinn
(Glendale, New York) model 151 recorder (0.1 Hz fre-
quency response) with a C-120 cassette tape. After adequate
skin preparation, leads were applied using V5 and either an
“inferior-like” lead or a historically defined lead showing
maximal ST-segment depression during ETT. Lead wires
were stabilized; patient instruction was provided; and site
personnel recorded approximately 8 min of 1-mV, 60-Hz,
rectangular-caliber impulses at the beginning of each re-
cording. Recordings were analyzed at the Ambulatory
Electrocardiogram Core Laboratory (eResearchTechnology,
Inc., Philadelphia, Pennsylvania), which was masked as to
the clinical data and treatment group assignment.
ST-segment measurement. The technician set one marker
at the mid-point of the PR segment and a second marker 20
ms to the right of the J point (where the ST-segment
measurement is made). A third marker was set 78 to 83 ms
to the right of the second marker for slope determination.
The vertical difference between where the first and second
calipers intersect the ECG was taken as the ST-segment
measurement for that beat; this measurement was made for
all normally conducted beats. Each measurement was then
compared with measurements for the three preceding nor-
mally conducted beats to determine whether it was contam-
inated by artifact. If not, the measurement was included in
the subsequent evaluation.
Definitions of ischemic episodes and ischemic burden
from ambulatory recordings. The baseline ST-segment
value was identified automatically as that value immediately
preceding an episode of ischemic ST-segment deviation
where the ST-segment value does not deviate more than
0.37 mm, compared with the preceding values. An ischemic
episode was defined as additional ST-segment depression of
1 mm from baseline lasting 1 min. The onset of an
episode was defined as that time when the ST-segment
deviation first satisfied the 1-mm criterion, compared
with baseline. The duration of an episode was the time
during which the ST-segment values were depressed 1
mm, compared with baseline. A new episode of ischemia
was defined when it was separated in time by 1 min from
the previous episode and met the aforementioned criteria.
The product of the number of ischemic episodes and their
duration per 24 h of analyzable recording was taken to
represent ischemic burden. The integral of ST-segment
depression over time was noted. For each patient and each
variable, the rank of the variable among the entire evaluable
population was obtained, and the two ranks were added for
each patient to form a composite variable.
Hemodynamic findings. Estimates of myocardial oxygen
demand were assessed by measurement of heart rate, systolic
blood pressure (brachial cuff), and rate-pressure product
(systolic blood pressure  heart rate) in the standing
position before and during each ETT.
Statistical considerations. STATISTICAL ANALYSES. Analy-
ses were performed on a modified intent-to-treat population
that included all randomized patients with baseline values
and at least one treatment period assessment. Randomized
patients were considered evaluable for the protocol analyses
if they had completed baseline and treatment period tread-
mill tests, complied with at least 80% of study medication,
and had not violated the protocol regarding interim proce-
dures or changes in medications.
The primary analysis, a priori, for treatment group
comparisons was treadmill test parameters using log-rank
tests based on Kaplan-Meier survival estimates at weeks 8
and 16. Mean and median values and standard deviations
were also compared. Treatment group comparisons for
ambulatory ECG parameters used an analysis of covariance
model with treatment and center as effects and with baseline
ambulatory ECG measurement and baseline low-density
lipoprotein cholesterol levels as covariates. The center was
included in the model as a fixed effect (41). Study centers
were not chosen randomly and represent a specific type of
facility. Randomization was also stratified by center.
Treatment-by-center and treatment-by-covariate interac-
tions also were examined. The O’Brien nonparametric
rank-sum method was used to analyze “ischemic burden”
(42).
SAMPLE SIZE CONSIDERATIONS. The trial was initially
planned for patients with ischemia during both ETT and
daily-life ambulatory monitoring. However, on the basis of
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our experience with other trials in similar patients and the
difficulty enrolling patients with both types of ischemia, an
interim analysis was planned to reassess power and recruit-
ment. Screening and recruitment results prompted a proto-
col modification to permit enrollment of patients with only
ischemia on treadmill testing and a satisfactory ambulatory
ECG study. For power estimates, time to onset 1-mm
ST-segment depression on ETT at eight weeks was chosen,
a priori, as the outcome of primary interest, and we assumed
that it would be desirable to increase this time by 25% in
those assigned to 40 mg quinapril over placebo to justify the
cost and inconvenience of adding an additional anti-
ischemic medication in this low-risk population. A sample
size of 336 patients (168 per treatment group) was chosen to
provide 95% power to detect a 25% increase in time to
1-mm ST-segment depression. This assumed a standard
deviation of 2.1%. This sample would provide approxi-
mately 60% power to detect a 50% decrease from placebo in
the number of ischemic episodes during ambulatory ECG
monitoring, assuming a coefficient of variation of 160%.
Power estimates used a two-sided significance of 0.05 and
assumed a 25% withdrawal rate.
RESULTS
Patient characteristics. The demographic and clinical
characteristics of the randomized patients by treatment
groups are summarized in Table 1. Most patients were
white men (mean age 64.5 years). Nearly one-half the
patients had medically treated hypertension, a previous MI,
or a remote revascularization procedure. Concomitant ther-
apy included a beta-blocker, statin, and nitrates in approx-
imately two-thirds of cases and calcium antagonists in
approximately one-half. Group 1 comprised 159 patients,
and group 2 comprised 177 patients. There were no signif-
icant differences in baseline characteristics between the
groups.
Exercise testing. All exercise parameters are summarized
for both treatment groups for each study period in Table 2.
Treatment groups were comparable at baseline in terms of
the time to onset of 1-mm ST-segment depression, angina,
and exercise duration. The times to 1-mm ST-segment
depression and level 2 angina for each treatment group are
displayed in a Kaplan-Meier fashion in Figures 2 and 3,
respectively. The difference between treatment groups was
not statistically significant (p  0.4816), although a trend
was noted for the time to level 2 angina (p 0.074) (Fig. 3).
Similar results were found after adjusting for gender, hy-
perlipidemia, and other baseline conditions.
At baseline, the mean time to 1-mm ST-segment depres-
sion (ischemia) was 4.2  0.1 min versus 4.3  0.1 min
(group 1 vs. group 2, p  0.639). After eight weeks, the
times to ischemia increased to 4.7  0.2 min and 4.8  0.2
min in the placebo and quinapril groups, respectively (p 
NS). The time to ischemia after an additional eight weeks
of treatment with 40 mg quinapril (Group 2) was 5.2  0.2
min and after 80 mg quinapril (Group 1), 5.0  0.2 min
(p  NS). The mean time to angina was 5.4  0.1 min
for group 1 and 5.5  0.1 min for group 2. After eight
weeks of treatment, the mean time to angina was 6.1  0.2
min for group 1 (placebo) and 6.6  0.2 min for group 2
(40 mg quinapril). The mean time to angina after 16 weeks
was 6.6  0.2 min for group 1 (80 mg quinapril) and
7.1  0.3 min for group 2 (40 mg quinapril). This dif-
ference was not statistically significant. At baseline, the
total exercise duration was 6.1 0.2 min and 6.4 0.2 min
with placebo and 40 mg quinapril groups, respectively
(p  NS). After eight weeks of treatment, values in-
creased to 6.4  0.2 min in the placebo group and 6.7 
0.2 min in the 40-mg quinapril group (mean change
Table 2. Effects on Exercise Indexes of Transient Ischemia
Group 1 Group 2
Treatment
Difference*
Baseline (period 1)
n 141 144
Time to STSD 4.2 0.1 4.3 0.1
Time to AP 5.4 0.1 5.5 0.1
Total ExT 6.1  0.2 6.4 0.2
Week 8 (period 2)
n 14,141 144
Time to STSD 4.7 0.2 4.8 0.2
Time to AP 6.1 0.2 6.6 0.2
Total ExT 6.4 0.2 6.7 0.2 0.23 (0.09 to 0.54)
Week 16 (period 3)
n 131 137
Time to STSD 5.0 0.2 5.2 0.2
Time to AP 6.6 0.2 7.1 0.3
Total ExT 6.7 0.19 6.9 0.196 0.03 (0.37 to 0.31)
*Least squares mean difference between treatment groups and 95% confidence interval
for the difference ( ) based on an analysis of covariance model with independent
variables representing treatment, center, baseline total exercise time, and baseline
low-density lipoprotein cholesterol.
n  number of patients with interpretable recordings by the exercise electrocar-
diography core laboratory; time to STSD  time (min) to onset of 1.0-mm
ST-segment depression; time to AP  time (min) to level 2 angina pectoris;
total ExT  total time (min) exercising on the treadmill. Data represent mean 
SEM.
Table 1. Baseline Demographics and Clinical Characteristics
Variable
Group 1
(n  159)
Group 2
(n  177)
Total
(n  336)
Age (yrs) 64.3  9.0 64.6  8.6 64.5  8.8
Male gender 128 (80.5%) 139 (78.5%) 267 (79.5%)
White race 157 (98.7%) 163 (92.1%) 320 (95.2%)
Medically treated
hypertension
82 (51.6%) 78 (44.1%) 160 (52.4%)
Diabetes mellitus type II 21 (13.2%) 20 (11.3%) 41 (12.2%)
Historical hyperlipidemia 130 (81.8) 147 (83.1) 227 (82.4)
Current smoker 15 (9.4) 19 (10.7) 34 (10.1)
Previous MI 63 (39.6) 72 (40.7) 135 (40.2)
Past revascularization 64 (40.3) 83 (46.9) 147 (43.8)
Concomitant medications
Beta-blocker 103 (64.8%) 117 (66.1%) 221 (65.5%)
Statin 99 (62.3%) 111 (62.7%) 210 (62.5%)
Nitrate 101 (63.5%) 107 (60.5%) 208 (61.9%)
Calcium antagonist 79 (49.7%) 81 (45.8%) 160 (47.6%)
Aspirin 152 (95.6%) 173 (97.7%) 325 (96.7%)
Data are presented as the mean value  SD or number (%) of patients.
MI  myocardial infarction.
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0.23 min; 95% confidence interval [CI] 0.09 to 0.54).
Treatment with 80 mg quinapril was not superior to
treatment with 40 mg quinapril (mean change 0.03 min;
95% CI 0.37 to 0.31). Although each of these measures
increased in both groups compared with the preceding study
period, the increases appeared related to training or time
effects, as no significant intergroup differences were detected
(Table 2, Fig. 4).
There were no significant changes in heart rate (Fig. 5),
systolic blood pressure (Fig. 6), or rate-pressure product
(data not shown) when comparing group 1 versus 2 at rest
or during exercise.
Ambulatory ECG monitoring. Distributions of the num-
ber of ischemic episodes per 24 h at baseline were similar
when comparing treatment groups, with 29.1% (37/127) of
patients in each group having no ischemic episodes (Table
3). Although fewer ischemic episodes occurred at week 8,
distributions of the number of ischemic episodes per 24 h
were similar for both groups, and no significant differences
between the groups were observed. The same was true for
week 16 data.
Seattle Angina Questionnaire. The mean values for the
five scores were very similar between the two groups at
baseline and at weeks 8 and 16 (data not shown). The score
for treatment satisfaction remained relatively constant for
both groups from baseline to weeks 8 and 16. Slight
improvements were seen at weeks 8 and 16 in the other
variables, compared with baseline. However, these changes
were similar in both groups.
Safety. Overall, quinapril at 40 and 80 mg was well
tolerated in this population, as the frequency of adverse
events was similar when comparing treatment groups. Two
cardiovascular deaths occurred, both in the 40-mg quinapril
group. The investigator treating the patients considered
both unrelated to the study medication. Three patients
experienced nonfatal MIs: two in the 40-mg quinapril group
and one in the placebo group. Investigators considered all
MIs to be unrelated to the study treatment.
There were no reports of significant changes in serum
electrolytes or renal function during the study. One week
after completing two weeks of treatment with 40 mg
quinapril, one patient withdrew from the study during
hospitalization for MI and was diagnosed with renal failure
at discharge. The study investigator considered the renal
failure to be probably related to quinapril treatment.
Thirty-six patients withdrew from the study because of
adverse events. Of the adverse events that led to withdrawal,
four were reported by more than two patients within a
treatment group. These included increased cough, rash,
increased angina, and chest pain. The only trend observed
was that cough occurred most often with 40 mg quinapril.
No patients withdrew from the study because of cardiac
Figure 2. Time (min) to induce 1-mm ST-segment depression during exercise treadmill test at 8 weeks of therapy—evaluable population. The percentage
of patients with ischemic-type ST-segment depression appears on the vertical axis, and time (min) is on the horizontal axis. There was no difference
between treatment group 1 (placebo) and group 2 (40 mg/day quinapril) at 8 weeks.
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adverse events during treatment with 80 mg quinapril.
However, two patients on this treatment withdrew because
of rash and one withdrew because of angioedema.
DISCUSSION
Recent studies have clearly shown ACE-I reduces adverse
cardiovascular outcomes in patients with CAD and those at
high risk of developing CAD (1–8). Whether a reduction of
transient ischemia potentially contributes to this benefit,
however, remains unclear, because previous studies had
small numbers of subjects with various confounding condi-
tions (e.g., heart failure, hypertension, syndrome X) and
treatment durations. Hence, the data available from previ-
ous studies (13–35), summarized in Table 4, are limited
when addressing this question. The QUASAR trial was the
first definitive study to assess ACE-I, per se, for improving
symptoms and signs of transient ischemia in patients with
CAD who did not have other indications (e.g., heart failure,
acute MI, uncontrolled hypertension) for ACE-I.
Episodes of transient ischemia might be precipitated by
increased myocardial oxygen demand in patients with flow-
limiting stenoses. Coronary constriction and/or a lack of
appropriate dilation as myocardial demand is increased also
may play a role in regions with (9,43,44) and without
(45–50) flow-limiting stenoses. Such abnormalities in cor-
onary vasomotion have been documented as related, at least
in part, to endothelial dysfunction (51). Lastly, quinapril
restores coronary endothelial function (9) and improves
coronary flow (11) in patients with CAD. Therefore, we
hypothesized that the ACE-inhibitory action of quinapril
might reduce transient ischemia in patients with stable
angina. However, although our results affirmed safety of
quinapril in medically treated, clinically stable CAD pa-
tients, we did not observe a significant reduction in transient
ischemia recorded during exercise or daily life.
The benefits of ACE-I for reducing the frequency of
clinical events in chronic heart failure, post-infarction,
post-coronary bypass patients, and even those with stable
atherosclerosis or at high risk of atherosclerosis, are docu-
mented (1–3,6–8,35,52,53). Our findings indicate that a
reduction of exercise-induced or daily-life ischemia is not
likely to be prominent among the possible mechanism(s)
responsible for decreasing adverse events. Quinapril at doses
of 40 or 80 mg/day had no significant effect on heart rate or
systolic blood pressure during exercise. For patients whose
heart rates and blood pressure responses were well con-
trolled by background anti-anginal agents, little additional
change was detected from the addition of ACE-I over an 8-
to 16-week period. These observations support the notion
that ischemia occurring in stable angina patients receiving
Figure 3. Time (min) to induce level 2 angina during exercise treadmill test at 8 weeks of therapy—evaluable population. The percentage of patients with
level 2 angina appears on the vertical axis, and time (min) is on the horizontal axis. There was no difference between treatment group 1 (placebo) and
group 2 (40 mg/day quinapril) at 8 weeks.
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anti-anginal drugs is very dependent on the severity of
relatively “fixed stenoses,” rather than vasomotor dysfunc-
tion at a distance from or in the neighborhood of flow-
limiting stenoses. Another possibility is that when high-risk
patients are excluded, a great many patients who could have
benefited were eliminated.
An additional factor that likely plays an important role in
these results is that the flow-limiting effects of vasomotor
changes on exertional and spontaneous ischemia are likely to
already have been modified by aggressive previous manage-
ment of risk factor conditions (e.g., hyperlipidemia, hyper-
tension). So, adding an ACE-I conferred little additional
benefit.
For example, baseline low-density lipoprotein C was 106
and 108 mg/dl among the two groups in this study. We
have previously found that an improvement in endothelial
function after six months of quinapril therapy is more
striking at higher levels of low-density lipoprotein C,
130 mg/dl (54).
It is also likely that vascular mechanisms leading to
clinical events known to be prevented by ACE-I (death,
MI, and hospitalization) differ from those leading to tran-
sient ischemia occurring during exercise or daily life. Thus,
the actions of chronic ACE-I to reduce these events may
depend more on increasing plaque stability and reducing
local thrombogenicity and less on modifying the vascular
motor dysfunction known to occur in chronic angina pa-
tients. Increased ACE activity has been observed in the
“shoulder region” of atherosclerotic plaque, which could
play a role in plaque rupture, thrombus formation, and rapid
progression of obstructive CAD (55). There is an improve-
ment of endothelial function with ACE-I in patients with
CAD and/or atherosclerotic risk factors (9,12,56). The
observation that the prognostic benefits of ACE-I have
been consistently shown to be independent of and additive
to those of beta-blockers is consistent with this concept, as
the latter have profound effects on the incidence of exercise-
induced and daily-life ischemia.
Figure 4. Summary of the three exercise (Ex) parameters for treatment groups 1 and 2. All exercise times increased over the study period (baseline to 8
weeks and 8 to 16 weeks). The increases were not associated with whether patients had received active drug, nor were they dose-dependent; thus, they are
likely to be training-related. ST SD  ST-segment depression.
Figure 5. Heart rate (beats/min) at peak exercise at baseline and at 8 and 16 weeks of therapy. There was no significant difference between treatment group
1 (open bars) and group 2 (solid bars).
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Study limitations. By design, ETT was not repeated
several times before entry, as in some anti-anginal treatment
studies, to eliminate patients with variable exercise ischemic
thresholds. We reasoned that this practice may help
select for a population with relatively fixed, fibrotic, or
calcific stenoses. We hypothesized that variability of time
to ischemic ST-segment depression and moderate angina
on ETT might be influenced by endothelial-mediated
vasomotion, and selecting those with highly reproducible
exercise times might, a priori, exclude those most likely
to derive benefit from ACE-I. Second, exercise results in
those randomized to placebo demonstrate the well-known
placebo and/or training effect, with an increase of 30-s
observed when comparing baseline and eight-week ETTs.
It is possible the effect of ACE-I on ischemia, if present,
is so modest it cannot be detected with ETT and a 30-s
placebo and/or training effect. Third, the duration of
quinapril treatment may not have been adequate to permit
its full effects to become manifest. We chose 8- and
16-week periods because this duration was sufficient to
demonstrate vascular effects in other studies using similar
patients (12,57). Another recent study found no improve-
ment in ETT or ambulatory ECG findings after one year
with a beneficial effect on cardiovascular adverse outcomes
(58). Furthermore, the benefits observed in other studies
required several years to become manifest, and the potential
vascular effects of ACE-I that lead to anti-anginal
effects may require more time to become manifest (1,2,7).
More recent trials in patients similar to those in
QUASAR have extended their duration of treatment
(59,60). Ongoing studies in this area may help clarify the
role of ACE-I and provide a rationale, other than a
reduction of transient ischemia, for using ACE-I in those
with CAD but without hypertension, heart failure, or
additional high-risk features.
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Figure 6. Systolic blood pressure (mm Hg) at peak exercise at baseline and at 8 and 16 weeks of therapy. There was no significant difference between
treatment group 1 (open bars) and group 2 (solid bars).
Table 3. Effects on Indexes of Spontaneous Ischemia/24 h
Group 1 Group 2 Treatment Difference*
Baseline (period 1)
n 127 127
No. of ischemic episodes† 1.7  2.3 1.4  1.7
No. with ischemia‡ 90 90 0.0 (11.2 to 11.2)
Week 8 (period 2)
n 127 127
No. of ischemic episodes† 1.3  2.3 0.9  1.3 0.16 (0.60 to 0.28)
No. with ischemia‡ 62 73 8.7 (3.6 to 20.9)
Change from baseline 0.4  2.2 0.4  1.8
Week 16 (period 3)
n 118 125
No. of ischemic episodes† 1.2  1.9 0.9  1.5 0.18 (0.60 to 0.23)
No. with ischemia‡ 67 58 10.4 (22.9 to 2.1)
Change from baseline 0.4  1.8 0.4  2.1
*Least squares mean difference between treatment groups and 95% confidence interval for difference based on an analysis of
covariance model with independent variables representing treatment, center, baseline value, and baseline low-density lipoprotein
cholesterol. †Episodes of ST-segment depression 1.0 mm persisting for 1 min per 24 h of recording. ‡Patients with one or
more ischemic episodes per 24 h of recording. Data are presented as the mean value  SEM.
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